Skip to main content

Table 3 Clinical summery of 11 ALS patients with respiratory dysfunction

From: Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients

ALS subjects El Escorial criteria ALSFRS-R Impairment Disease duration at sample collection (mo)
Patient 1 Definite 27 Moderate 12
Patient 2 Definite 23 Severe 12
Patient 3 Definite 18 Severe 24
Patient 4 Definite 16 Severe 18
Patient 5 Definite 29 Moderate 12
Patient 6 Definite 29 Moderate 04
Patient 7 Definite 29 Moderate 09
Patient 8 Definite 31 Moderate 08
Patient 9 Definite 35 Moderate 24
Patient 10 Probable 34 Moderate 12
Patient 11 Probable 35 Moderate 30
  1. ALSFRS-R: ALS functional rating score-revised; Impairment was measured with ALSFRS-R. ‡ Duration of disease is the interval between appearance of first symptom of ALS and collection of sample. Median disease duration in patients with respiratory dysfunction is 12(4-30) months whereas median duration of disease was 17(3-72) months in patients without respiratory dysfunction, although the observed difference was not significant upon Mann-Whitney U analysis (p > 0.05).